Repligen to Acquire Metenova AB

Favorable financial impact of Metenova acquisition LI R REPLIGEN Expected to add $25M-$27M of revenue in 2024 and to grow 20%-25% in 2025 forward Gross margins above Repligen's 2023e margins, in line with Repligen historical and LT goal of 55%-60% 2024 investment focus: Expansion of single-use mixing solutions, commercial integration Synergies with current portfolio and mutual commercial leverage points Expected to be accretive to adjusted gross and operating margins in 2024 Expected to be accretive to adjusted EPS in 2025 metem nova 8

View entire presentation